Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Shailesh Arjun Bondarde"'
Autor:
Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B. J. Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou, Yi-Long Wu
Publikováno v:
Targeted Oncology
Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clini
Autor:
Gopichand Mamillapalli, Ghanashyam Biswas, Guruprasad Bhat, Nisarg Joshi, Pramod Patil, Tanveer Maksud, Vinay Bajaj, Sudeep Gupta, Kakali Choudhury, Mujtaba A Khan, Suresh Babu, Gopal Raja, Apurva A. Patel, Jayanti G. Patel, Kuntegowdennahalli C. Lakshmaiah, Piyush M. Patel, Shailesh Arjun Bondarde, Rakesh R. Boya, Rakesh Neve
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 60, Iss, Pp 147-154 (2021)
Breast, Vol 60, Iss, Pp 147-154 (2021)
Aim To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy. Methods In this prosp
Autor:
Shekar Patil, Raju Titus Chacko, Rajesh Naik, M V Chandrakant, Deepak Dabkara, Shyam Aggarwal, Dinesh Chandra Doval, Chirag Desai, Sohit Anand, Ashok K. Vaid, Shailesh Arjun Bondarde, Kumar Prabhash, Senthil Rajappa, Purvish M. Parikh, Palanki Satya Dattatreya, T. P. Sahoo, Vanita Noronha, G. Biswas, Vijay Patil, Pratap Kishore Das, Amit Joshi
Publikováno v:
South Asian Journal of Cancer
South Asian Journal of Cancer, Vol 7, Iss 3, Pp 203-206 (2018)
South Asian Journal of Cancer, Vol 7, Iss 3, Pp 203-206 (2018)
Background: We conducted a survey of 111 medical oncologists across India to understand the current pattern of epidermal growth factor receptor (EGFR) mutation testing at their respective centers. Methods: Medical oncologists from 111 institutes acro
Autor:
Shailesh Arjun Bondarde, Sankar Srinivasan, Binay Swarup, Dinesh Chandra Doval, Senthil Rajappa, Nitin S Palwe, Naresh Somani, Jaydip Biswas, Shekar Patil
Publikováno v:
South Asian Journal of Cancer
South Asian Journal of Cancer, Vol 6, Iss 1, Pp 1-5 (2017)
South Asian Journal of Cancer, Vol 6, Iss 1, Pp 1-5 (2017)
Bacground: First-line maintenance with erlotinib in nonsmall cell lung cancer (NSCLC) patients without progression after four cycles of chemotherapy was well tolerated and significantly prolonged progression-free survival (PFS) compared with placebo.
Autor:
Narayanankutty Warrier, Vijay Patil, Adwaita Gore, Govind Babu, Shekhar Patil, Nirmal Vivek Raut, Kumar Prabhash, Nitesh Rohatgi, Amish Vora, Bharat Bhosale, Shailesh Arjun Bondarde, Vanita Noronha, T. P. Sahoo, Sewanti Limaye, Bharat Vaswani, Ullas Batra
Publikováno v:
Cancer Research, Statistics, and Treatment. 4:279
The management of patients with advanced non-small-cell lung cancer (NSCLC) is becoming increasingly complex, with the identification of driver mutations/rearrangements and the development and availability of appropriate targeted therapies. In 2018,
Autor:
Poonam Patil, A. Bakshi, Raghunadharao Digumarti, K Govind Babu, Chiramana Haritha, Niraj Bhatt, Sundaram Subramanian, Minish Mahendra Jain, Shravanti Bhowmik, Smita Uday Gupte, Gouri Sankar Bhattacharya, Jyoti Bajpai, Shailesh Arjun Bondarde, Ravi Kumar, Chetan Deshmukh, Geetanjali Chimote, Ashok K. Vaid, Ajay Khopade, Anand Pathak, Shekhar Patil, P P Bapsy, Chirag Desai
Publikováno v:
Breast Cancer Research and Treatment
Paclitaxel is widely used in the treatment of patients with metastatic breast cancer (MBC). Formulations of paclitaxel contain surfactants and solvents or albumin derived from human blood. The use of co-solvents such as polyoxyethylated castor oil is
Autor:
D. Lokanatha, Minish Mahendra Jain, Virginia G. Kaklamani, Lee S. Schwartzberg, Wj. Gradishar, Shailesh Arjun Bondarde, Vinod Raina, T. Prasad Sahoo
Publikováno v:
Cancer Research. 70:P2-16
Background: Sorafenib (SOR) is an oral multikinase inhibitor that targets tumor growth and angiogenesis. We previously reported progression-free survival (PFS) data from the primary analysis of NU07B1 (SABCS 2009 abstr 44), a phase 2b trial assessing
Autor:
B. Rangrajan, Randeep Singh, Anantbhushan Ranade, Dinesh Chandra Doval, Hemant Malhotra, Shailesh Arjun Bondarde, GS Bhattacharya, Purvish M. Parikh, K. Babu Govind, P. M. Shah, P. Bhavesh, Prashant Mehta, Amit Verma, Sachin Hingmire, N. Ghadyalpatil
Publikováno v:
International Journal of Molecular and Immuno Oncology. 2:47
Advances in molecular oncology technology and their application to personalized cancer care have evolved very rapidly over the past 5 years. At the same time, there are a lot of conflicting and often misleading statements available on the world wide
Autor:
Raju Titus Chacko, Purvish M. Parikh, Ghanashyam Biswas, Shailesh Arjun Bondarde, Deepak Dabkara, Kumar Prabhash, Vijay Patil, Chandrakanth Mv, Vanita Noronha, Pratap Kishore Das, Dinesh Chandra Doval, Shekar Patil, Rajesh Naik, Shyam Aggarwal, Ashok K. Vaid, Chirag Desai, Senthill J Rajappa, T. P. Sahoo, Amit Joshi, Sohit Anand
Publikováno v:
Journal of Clinical Oncology. 35:e13111-e13111
e13111 Background: Lung cancer diagnosis now involves routine use of biomarker testing to identify the driver mutations. We conducted a survey of 111 medical oncologists across India to understand the current pattern of EGFR mutation testing at their
Autor:
Shailesh Arjun Bondarde, Nathalie A. Lokker, T. P. Sahoo, Minish Mahendra Jain, Sunhee Ro, Virginia G. Kaklamani, Vinod Raina, Lee S. Schwartzberg, Dasappa Lokanatha, William J. Gradishar
Publikováno v:
European journal of cancer (Oxford, England : 1990). 49(2)
Background We conducted a phase 2b, randomised, double-blind, placebo-controlled screening trial to evaluate the addition of the multikinase inhibitor sorafenib (antiproliferative/antiangiogenic) to first-line paclitaxel for human epidermal growth fa